Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 5 de 5
2.
Free Radic Biol Med ; 210: 448-461, 2024 01.
Article En | MEDLINE | ID: mdl-38036067

Non-alcoholic steatohepatitis (NASH) is one of the fastest growing liver diseases worldwide, and oxidative stress is one of NASH main key drivers. Nicotinamide adenine dinucleotide phosphate (NADPH) is the ultimate donor of reductive power to a number of antioxidant defences. Here, we explored the potential of increasing NADPH levels to prevent NASH progression. We used nicotinamide riboside (NR) supplementation or a G6PD-tg mouse line harbouring an additional copy of the human G6PD gene. In a NASH mouse model induced by feeding mice a methionine-choline deficient (MCD) diet for three weeks, both tools increased the hepatic levels of NADPH and ameliorated the NASH phenotype induced by the MCD intervention, but only in female mice. Boosting NADPH levels in females increased the liver expression of the antioxidant genes Gsta3, Sod1 and Txnrd1 in NR-treated mice, or of Gsr for G6PD-tg mice. Both strategies significantly reduced hepatic lipid peroxidation. NR-treated female mice showed a reduction of steatosis accompanied by a drop of the hepatic triglyceride levels, that was not observed in G6PD-tg mice. NR-treated mice tended to reduce their lobular inflammation, showed a reduction of the NK cell population and diminished transcription of the damage marker Lcn2. G6PD-tg female mice exhibited a reduction of their lobular inflammation and hepatocyte ballooning induced by the MCD diet, that was related to a reduction of the monocyte-derived macrophage population and the Tnfa, Ccl2 and Lcn2 gene expression. As conclusion, boosting hepatic NADPH levels attenuated the oxidative lipid damage and the exhausted antioxidant gene expression specifically in female mice in two different models of NASH, preventing the progression of the inflammatory process and hepatic injury.


Non-alcoholic Fatty Liver Disease , Female , Mice , Humans , Animals , Non-alcoholic Fatty Liver Disease/drug therapy , Non-alcoholic Fatty Liver Disease/genetics , Non-alcoholic Fatty Liver Disease/metabolism , NADP/metabolism , Antioxidants/metabolism , Liver/metabolism , Inflammation/metabolism , Choline/metabolism , Methionine/metabolism , Mice, Inbred C57BL , Disease Models, Animal
3.
Nat Commun ; 14(1): 2779, 2023 05 15.
Article En | MEDLINE | ID: mdl-37188705

Reversible and sub-lethal stresses to the mitochondria elicit a program of compensatory responses that ultimately improve mitochondrial function, a conserved anti-aging mechanism termed mitohormesis. Here, we show that harmol, a member of the beta-carbolines family with anti-depressant properties, improves mitochondrial function and metabolic parameters, and extends healthspan. Treatment with harmol induces a transient mitochondrial depolarization, a strong mitophagy response, and the AMPK compensatory pathway both in cultured C2C12 myotubes and in male mouse liver, brown adipose tissue and muscle, even though harmol crosses poorly the blood-brain barrier. Mechanistically, simultaneous modulation of the targets of harmol monoamine-oxidase B and GABA-A receptor reproduces harmol-induced mitochondrial improvements. Diet-induced pre-diabetic male mice improve their glucose tolerance, liver steatosis and insulin sensitivity after treatment with harmol. Harmol or a combination of monoamine oxidase B and GABA-A receptor modulators extend the lifespan of hermaphrodite Caenorhabditis elegans or female Drosophila melanogaster. Finally, two-year-old male and female mice treated with harmol exhibit delayed frailty onset with improved glycemia, exercise performance and strength. Our results reveal that peripheral targeting of monoamine oxidase B and GABA-A receptor, common antidepressant targets, extends healthspan through mitohormesis.


Aging , Antidepressive Agents , Harmine , Mitochondria , Mitophagy , Monoamine Oxidase , Receptors, GABA-A , Harmine/analogs & derivatives , Harmine/pharmacology , Antidepressive Agents/pharmacology , Mitochondria/drug effects , Mitophagy/drug effects , Muscle Fibers, Skeletal/drug effects , AMP-Activated Protein Kinase Kinases/metabolism , Muscle, Skeletal/drug effects , Liver/drug effects , Aging/drug effects , Insulin Resistance , Glucose Intolerance/metabolism , Prediabetic State/metabolism , Monoamine Oxidase/metabolism , Receptors, GABA-A/metabolism , Longevity/drug effects , Caenorhabditis elegans , Drosophila melanogaster , Frailty/prevention & control , Physical Conditioning, Animal , Models, Animal , Male , Female , Animals , Mice , Fatty Liver/metabolism , Adipose Tissue, Brown/drug effects
4.
Nat Commun ; 13(1): 5677, 2022 09 27.
Article En | MEDLINE | ID: mdl-36167809

Fasting exerts beneficial effects in mice and humans, including protection from chemotherapy toxicity. To explore the involved mechanisms, we collect blood from humans and mice before and after 36 or 24 hours of fasting, respectively, and measure lipid composition of erythrocyte membranes, circulating micro RNAs (miRNAs), and RNA expression at peripheral blood mononuclear cells (PBMCs). Fasting coordinately affects the proportion of polyunsaturated versus saturated and monounsaturated fatty acids at the erythrocyte membrane; and reduces the expression of insulin signaling-related genes in PBMCs. When fasted for 24 hours before and 24 hours after administration of oxaliplatin or doxorubicin, mice show a strong protection from toxicity in several tissues. Erythrocyte membrane lipids and PBMC gene expression define two separate groups of individuals that accurately predict a differential protection from chemotherapy toxicity, with important clinical implications. Our results reveal a mechanism of fasting associated with lipid homeostasis, and provide biomarkers of fasting to predict fasting-mediated protection from chemotherapy toxicity.


Fasting , MicroRNAs , Animals , Biomarkers , Doxorubicin/toxicity , Fasting/metabolism , Fatty Acids/metabolism , Fatty Acids, Monounsaturated , Homeostasis , Humans , Insulin , Leukocytes, Mononuclear/metabolism , Mice , Oxaliplatin
5.
Aging (Albany NY) ; 12(12): 11337-11348, 2020 06 25.
Article En | MEDLINE | ID: mdl-32584785

Senescent cells accumulate with obesity in the white adipose tissue of mice and humans. These senescent cells enhance the pro-inflammatory environment that, with time, contributes to the onset of glucose intolerance and type 2 diabetes. Glucose intolerance in mouse models of obesity has been successfully reversed by the elimination of senescent cells with the senolytic compounds navitoclax or the combination of dasatinib and quercetin (D/Q). In this work, we generated obese mice by high-fat diet feeding, and treated them with five consecutive cycles of navitoclax or D/Q during 16 weeks. We observed an efficient reduction in the white adipose tissue of the senescence markers senescence-associated ß-galactosidase activity, Cdkn2a-p16 and Cdkn2a-p19 at the end of the 5 cycles. Mice treated with both navitoclax and D/Q showed an improvement of their insulin sensitivity and glucose tolerance during a short period of time (cycles 3 and 4), that disappeared at the fifth cycle. Also, these mice tended to increase the expression at their adipose tissue of the adipogenic genes Pparg and, Cebpa, as well as their plasma adiponectin levels. Together, our work shows that two different senolytic treatments, acting through independent pathways, are transiently effective in the treatment of obesity-induced metabolic disorders.


Aniline Compounds/administration & dosage , Cellular Senescence/drug effects , Dasatinib/administration & dosage , Obesity/drug therapy , Quercetin/administration & dosage , Sulfonamides/administration & dosage , Adipogenesis/drug effects , Adiponectin/blood , Adiponectin/metabolism , Adipose Tissue, White/cytology , Adipose Tissue, White/drug effects , Adipose Tissue, White/metabolism , Animals , CCAAT-Enhancer-Binding Proteins/metabolism , Cellular Senescence/physiology , Diet, High-Fat/adverse effects , Disease Models, Animal , Drug Administration Schedule , Drug Combinations , Glucose Intolerance/blood , Glucose Intolerance/drug therapy , Glucose Intolerance/etiology , Glucose Intolerance/metabolism , Humans , Insulin Resistance , Male , Mice , Mice, Obese , Obesity/blood , Obesity/etiology , Obesity/metabolism , PPAR gamma/metabolism
...